Apixaban and Tingling in Legs
Tingling in both legs is a recognized neurological adverse effect of apixaban that requires immediate medical evaluation and may necessitate discontinuation of the medication.
Critical Warning from FDA Drug Label
The FDA-approved prescribing information for apixaban explicitly warns: "Tell your doctor right away if you have tingling, numbness, or muscle weakness, especially in your legs and feet" 1. This warning appears in the context of spinal or epidural hematoma risk, but the symptom itself warrants urgent assessment regardless of whether the patient has had spinal procedures.
Clinical Evidence of Neurological Effects
A documented case report describes an 80-year-old woman who developed neurological symptoms within days of starting apixaban, including:
- Non-vertiginous dizziness
- Headache
- Confusion/disorientation
- Imbalance
- Asthenia
Her symptoms completely resolved within 72 hours of stopping apixaban, and her plasma apixaban concentration was 4 times higher than the laboratory upper limit of normal 2. This case demonstrates that apixaban can cause reversible neurological adverse reactions, particularly in elderly patients or those with renal impairment.
Immediate Action Required
When a patient on apixaban reports tingling in both legs, you must:
Rule out spinal/epidural hematoma emergently - This is a medical emergency that can cause permanent paralysis. Look specifically for:
- Progressive weakness
- Bowel/bladder dysfunction
- Sensory level
- Recent spinal procedures or epidural catheter placement 1
Assess for drug accumulation - Check:
- Renal function (creatinine clearance)
- Recent dose changes
- Concurrent medications (CYP3A4 inhibitors, P-glycoprotein inhibitors)
- Patient age and weight (dose reduction criteria) 3
Evaluate for other serious complications:
- Bleeding manifestations (check hemoglobin, signs of occult bleeding)
- Peripheral neuropathy from other causes
- Vascular insufficiency
Management Algorithm
If spinal hematoma is suspected: Obtain urgent MRI and neurosurgical consultation. Consider reversal with andexanet alfa or 4-factor PCC 4, 3.
If drug accumulation is identified:
- Hold apixaban immediately
- Measure apixaban-calibrated anti-Xa levels if available 5
- Consider dose reduction or alternative anticoagulant once symptoms resolve
- In elderly patients or those with CrCl 15-30 mL/min, apixaban levels can remain detectable for >10 days 5
If neurological adverse reaction is suspected:
- Discontinue apixaban
- Monitor for symptom resolution (typically within 72 hours) 2
- Consider switching to alternative anticoagulant (e.g., rivaroxaban, as demonstrated in the case report) 2
- Do NOT simply continue the medication
Common Pitfalls
- Dismissing neurological symptoms as unrelated to anticoagulation - The FDA label specifically warns about tingling/numbness, making this a recognized adverse effect
- Failing to check renal function - Apixaban is 27% renally eliminated, and accumulation occurs with renal impairment 6
- Not considering drug interactions - Strong CYP3A4 and P-glycoprotein inhibitors significantly increase apixaban levels 3
- Assuming all neurological symptoms are from bleeding - Direct neurological toxicity can occur without hemorrhage 2
Risk Factors for Neurological Effects
Patients at higher risk include:
- Advanced age (≥80 years)
- Chronic kidney disease
- Low body weight (<60 kg)
- Concurrent use of CYP3A4/P-glycoprotein inhibitors
- Supratherapeutic dosing 2, 7
The bottom line: Tingling in both legs while on apixaban is not a symptom to observe—it requires immediate evaluation, potential drug discontinuation, and consideration of alternative anticoagulation strategies.